|
Targeted Therapies for Breast Cancer and Practical Patient Management Strategies
Therapeutic options for patients with breast cancer have evolved with the increasing understanding of the cellular and molecular pathways involved in survival and proliferation of breast cancer cells. Recent advances with targeted or biological therapies provide the basis for more individualized management of breast cancer patients. An understanding of the molecular basis for targeted therapies, as well as the safety and efficacy of these treatments are essential for the integration of these therapeutic options into the clinical care of patients with breast cancer.
NEEDS STATEMENT/TARGET AUDIENCE
This activity is intended to provide oncologists and other healthcare professionals with the latest information on targeted therapies for breast cancer and practical patient management strategies.
EDUCATIONAL ACTIVITY LEARNING OBJECTIVES
Upon completion of this activity, the participants should be able to:
- Explain the molecular basis of targeted therapies for breast cancer
- Identify the characteristics of the patients most likely to benefit from each type of therapy
- Consider expert opinion and ongoing clinical trial results when making targeted therapeutic decisions for breast cancer management
- Discuss the potential side effects of each type of therapy
- Develop an individualized management plan for each breast cancer patient based on the clinical, biologic, and molecular characteristics of their tumor
ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT STATEMENTS
PHYSICIANS
The France Foundation designates each Peer-to-Peer Dialogue for a maximum of .25 AMA PRA Category 1 Credit™.
The France Foundation designates the e-Monograph for a maximum of 1 AMA PRA Category 1 Credit™.
The France Foundation designates the Interactive Case for a maximum of 1 AMA PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
PHARMACISTS
The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award CEUs to pharmacists who complete each activity, complete the registration and evaluation forms, and successfully pass a posttest (>70%). There is no fee required to participate in this activity. Statements of credit will be sent within 4-6 weeks.
Peer-to-Peer ACPE No. 391-000-09-003-H01-P (Must complete all 3 Peer-to-Peer)
e-Monograph ACPE No. 391-000-09-001-H01-P
Interactive Case ACPE No. 391-000-09-002-H01-P
NURSES
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This educational activity is sponsored by The France Foundation and is supported by unrestricted educational grants from Genentech and GlaxoSmithKline.
RELEASE/EXPIRATION DATES
This activity is eligible for credit from January 2009 through December 31, 2009.
FACULTY
Aman U. Buzdar, MD
Professor of Medicine
Department of Breast Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Charles E. Geyer Jr, MD, FACP
Vice Chairman
Department of Human Oncology
Allegheny General Hospital
Pittsburgh, Pennsylvania
Associate Professor of Human Oncology
Drexel University College of Medicine
Philadelphia, Pennsylvania
William J. Gradishar, MD
Professor of Medicine
Director of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Faculty Disclosure
It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a faculty member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.
Aman U. Buzdar, MD, has received grants/research support from AstraZeneca, Eli Lilly, Genentech, Pfizer, Roche, and Taiho. He has received honoraria from Amgen, AstraZeneca, Genentech, and Pfizer.
Charles E. Geyer Jr, MD, FACP, has nothing to disclose.
William J. Gradishar, MD, has served as a consultant for Abraxis Oncology, AstraZeneca, Bristol-Myers Squibb, Eisai, Genentech, Novartis, Pfizer, and Roche.
DISCLAIMER
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Genentech, and GlaxoSmithKline assume no liability for the information herein.
|
